Author Archives: Bruno Quinney

Human heart
#AskBio #Gene therapy #Heart failure

Gene therapy could treat congestive heart failure

Gene therapy company AskBio has announced encouraging results from the Phase I trial of gene therapy AB-1002 in participants with congestive heart failure.  The 12-month data set, revealed in Nature Medicine, confirms that meaningful improvements were recorded across several efficacy assessments and no adverse events… Read More

#News

Patient with type 1 diabetes
#FDA #Sanofi #Type 1 diabetes

FDA expedites review of Sanofi’s Type 1 diabetes drug

The US Food and Drug Administration (FDA) has accepted Sanofi’s Stage 3 Type 1 diabetes drug, Tzield, for expedited review.  Tzield delays the progression of Stage 3 Type 1 diabetes (T1D) in patients eight years or older who have recently been diagnosed. Sanofi’s drug received expedited review as one of… Read More

#News #Regulatory

#Antimicrobial resistance (AMR) #Biotech #Vaccines

A universal approach to vaccines 

DDW Editor Reece Armstrong speaks to Dr Neil Murray, CEO of Liverpool-based RenewVax, that is developing the first universal vaccine for invasive pneumococcal disease, as well as vaccines for other antimicrobial resistant bacterial infections.   RA: What’s the current unmet need in terms of preventing and treating pneumococcal disease?   NM:… Read More

#Exclusive Content

#Antivirals #Coronavirus

Open science collaboration reveals promising new coronavirus antiviral

A promising broad-spectrum coronavirus antiviral pre-clinical candidate, ASAP-0017445, has been discovered.  ASAP-0017445 is designed to be a direct-to-generic, globally accessible treatment ready for future coronavirus pandemics. The pre-clinical drug candidate, which exhibited encouraging preliminary safety and efficacy results, was recently nominated by Drugs for Neglected Diseases initiative… Read More

#News

#Cancer research #Gut microbiome #Microbiotica #Ulcerative colitis (UC)

Unravelling the modes of action of microbiome therapies

Tim Sharpington, Chief Executive Officer at Microbiotica, and Matthew Robinson, SVP Research, Microbiotica, discuss the opportunities for precision-based microbiome therapeutics and which diseases could benefit the most from this approach.   The development of genetic techniques to analyse the microbiome has triggered a massive expansion of research into our relationship with… Read More

#Exclusive Content

T cell attacking cancer cell
#Cancer research #Immunotherapy #Japan

‘Signature’ genes could determine immunotherapy success

Scientists have identified a set of ‘signature’ genes that can determine the success of immune cells inside cancer tumours.  Research published in Nature Communications reveals that scientists at the University of Tokyo, Japan identified whether CD8+ T cells, a type of immune cell, will multiply… Read More

#News

UK financial markets
#AIDs #Malaria #Tuberculosis #UK government

GSK and ViiV Healthcare invest £6 million in Global Fund

Pharmaceutical companies GSK and ViiV Healthcare have invested £6 million ($8 million) in the Global Fund to Fight AIDS, Tuberculosis and Malaria.  The investment will strengthen community-led responses to HIV, tuberculosis (TB) and malaria in lower income countries. The commitment will also be matched by the Gates… Read More

#News

#Mosaic Therapeutics #Oncology

Thomas Fuchs appointed CEO of Mosaic Therapeutics

Oncology therapeutics company Mosaic Therapeutics has appointed Thomas Fuchs as its CEO.  Fuchs has over 25 years of experience in leadership positions across early drug development, commercialisation and life cycle management, serving in senior oncology biopharma leadership roles in both oncology-focused biotech and big pharma. He was… Read More

#News

#Biopharma #Pharmaceutical #RedHill Biopharma

Cumberland Pharmaceuticals invests $4 million in Talicia

Specialty pharmaceuticals company Cumberland Pharmaceuticals has invested $4 million in Talicia, the global product developed by biopharmaceutical company RedHill Biopharma.  Talicia is the number one branded US gastroenterologist-prescribed H. pylori therapy, listed as a first-line H. pylori therapy in American College of Gastroenterology Clinical Guidelines. It remains the only FDA-approved all-in-one, low-dose rifabutin-based H. pylori therapy… Read More

#Business & Investment #News

Medical laboratory
#Antibody drug conjugate (ADC) #Drug discovery #India

Globalising ADC development in the US and beyond

Srivats Rajagopal explores the growth of the antibody-body conjugate (ADC) market, development trends and why innovators are turning towards India. The ADC field has reached an inflection point. In 2022, Enhertu, Kadcyla, and Trodelvy together accounted for more than $4 billion of the $4.7 billion in global ADC revenues, and over… Read More

#Exclusive Content

UK
#Clinical trial #National Institute for Health Research #UK

UK’s NIHR aims to bring commercial research into primary care 

The UK’s National Institute for Health and Care Research (NIHR) has announced plans to establish 14 centres to expand commercial research delivery and improve access to clinical trials.  As revealed in the announcement, NIHR has awarded more than £14 million ($19 million) to GP-led primary care organisations… Read More

#News

#Europe #European Union #Precision medicine

EU backs Swiss Rockets Serbia precision medicine hub

Biotech company Swiss Rockets Serbia has signed a Joint Declaration of Intent with the European Commission (DG ENEST) and the Development Agency of Serbia (RAS) to establish a regional centre of excellence for precision medicine.  The joint declaration announces the ambition of Swiss Rockets Serbia, a subsidiary of Swiss Rockets… Read More

#Business & Investment #News

#Breast cancer #DDW Highlights podcast #Drug therapy #Gene therapy #Prostate cancer

DDW Highlights: 21 October 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed drug therapies could prevent hereditary diseases. Elsewhere, there were… Read More

#Podcasts

#Breast cancer #DNA mutations #Drug therapy #Gene therapy #Prostate cancer #sympos

This week in Drug Discovery (13 – 17 October)

News round-up for 13 – 17 October by Bruno Quinney, Content Team at DDW.  This week’s top story comes from new research showing drug therapies could prevent hereditary diseases. Elsewhere, there have been major developments in cancer research and gene therapy could help combat hearing loss. … Read More

#News

#AI #Clinical trial #Thermo Fisher Scientific

Thermo Fisher announces collaboration with OpenAI

Biotechnology company Thermo Fisher has announced plans to increase the impact of its growth strategy using artificial intelligence (AI) with OpenAI.  Thermo Fisher believes the collaboration with OpenAI will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost… Read More

#Business & Investment #News